DOI: 10.1055/s-00000009

American Journal of Perinatology

References

The IMpact-RSV Study Group.
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants.

Pediatrics 1998;
102 (3, Pt 1): 531-537

Download Bibliographical Data

Search in:
Access: